EXAI News and Press, Exscientia Limited From 08/10/23

Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below. Exscientia will host a conference call Thursday, August 10 at 1:30 p.m. BST / 8:3...

2023-08-04 06:00:11 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Many investors, including a significant number of very wealthy individuals and institutions, are becoming enthralled with AI stocks . According to Goldman Sachs (NYSE: ...

Company to host conference call and webcast on August 10, 2023, at 1:30 p.m. BST / 8:30 a.m. EDT Exscientia plc (Nasdaq: EXAI) will report financial results for the second quarter ended June 30, 2023, on Thursday August 10, 2023, before the open of U.S. markets. The Company will host a ...

2023-08-01 18:19:34 ET Summary Exscientia, a pioneer in AI-driven drug development, is using artificial intelligence to accelerate the discovery and preclinical phases of drug development. The company's stock traded higher after starting a Phase 1/2 trial for a new cancer therapy,...

First multi-centre trial, EXCYTE-1, evaluating the potential of Exscientia’s functional precision medicine platform in solid tumour indication Builds off of pioneering AI-guided functional precision medicine research in haematological cancers Exscientia plc (Nasdaq: EXAI)...

2023-07-14 11:53:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The past year provided a peek into the future of biotech and healthcare. Megafirms like Medtronic (NYSE: MDT ) led the way, partnering with tech giants such as...

2023-07-12 16:51:00 ET Shares of Exscientia (NASDAQ: EXAI) were up 12% as of Wednesday's close, two days after the clinical-stage healthcare company said it had begun enrollment on a phase 1/2 clinical trial looking at an advanced solid-tumor therapy. The stock is up more than 3...

2023-07-10 12:43:50 ET The ADRs of Exscientia plc ( NASDAQ: EXAI ) traded higher on Monday after the U.K.-based biotech and its Chinese partner GT Apeiron announced the enrollment of the first patient in their Phase 1/2 trial for an experimental cancer therapy called GTAEXS617. ...

- Precision-designed potent and selective CDK7 inhibitor with potential for improved therapeutic index - - Preclinically discovered non-invasive PD biomarker to be confirmed alongside clinical trial - Exscientia plc (Nasdaq: EXAI) today announced that it has enrolled the first...

- Preclinical data from AI-optimized GTAEXS617 support potential for improved therapeutic index compared to other CDK7 inhibitors under development - - Parallel translational initiative to evaluate preclinically identified non-invasive PD biomarkers with potential to predict GTAEXS6...